$11.92
0.67% yesterday
Nasdaq, Sep 19, 10:10 pm CET
ISIN
BMG762791017
Symbol
ROIV
Sector
Industry

Roivant Sciences Stock price

$11.92
+0.43 3.74% 1M
+1.99 20.04% 6M
+0.69 6.14% YTD
+1.12 10.37% 1Y
+2.57 27.49% 3Y
+2.57 27.49% 5Y
+2.57 27.49% 10Y
Nasdaq, Closing price Thu, Sep 19 2024
-0.08 0.67%
ISIN
BMG762791017
Symbol
ROIV
Sector
Industry

Key metrics

Market capitalization $8.87b
Enterprise Value $4.03b
P/E (TTM) P/E ratio 2.15
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 25.45
P/S ratio (TTM) P/S ratio 56.06
P/B ratio (TTM) P/B ratio 1.63
Revenue growth (TTM) Revenue growth 101.44%
Revenue (TTM) Revenue $158.30m
EBIT (operating result TTM) EBIT $-1.05b
Free Cash Flow (TTM) Free Cash Flow $-710.11m
Cash position $5.68b
EPS (TTM) EPS $5.57
P/E forward negative
P/S forward 45.92
EV/Sales forward 20.85
Short interest 6.85%
Show more

Is Roivant Sciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.

Roivant Sciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Roivant Sciences forecast:

11x Buy
92%
1x Hold
8%

Analyst Opinions

12 Analysts have issued a Roivant Sciences forecast:

Buy
92%
Hold
8%

Financial data from Roivant Sciences

Assets
Mar '24
6,732 6,732
Cash 6,541 6,541
Claims 83 83
Inventories 35 35
Other current assets Other current assets Current assets 73 73
491 491
Property, plant and equipment 66 66
Financial assets 257 257
Intangible Assets 138 138
Other fixed assets Other assets Fixed assets 30 30
Total Assets 7,222 7,222
Liabilities
Mar '24
Equity 6,449 6,449
774 774
Current liabilities 267 267
Non-current liabilities 507 507
Total Capital 7,222 7,222

In millions USD.

Don't miss a Thing! We will send you all news about Roivant Sciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Roivant Sciences Stock News

Positive
Barrons
one day ago
Selling plaque psoriasis drug Vtama to Organon looks like another win for Roivant, which has been buying overlooked drugs, and then selling them for big returns.
Neutral
GlobeNewsWire
one day ago
VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an additional indication to treat atopic dermatitis
Neutral
Business Wire
one day ago
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon enters agreement to acquire Dermavant including innovative VTAMA (tapinarof) cream, 1%, a novel, non-steroidal topical dermatologic therapy.
More Roivant Sciences News

Company Profile

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.

Head office Bermuda
CEO Matthew Gline
Employees 908
Founded 2014
Website www.roivant.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today